BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 36881759)

  • 1. Chemistry, structure and function of approved oligonucleotide therapeutics.
    Egli M; Manoharan M
    Nucleic Acids Res; 2023 Apr; 51(6):2529-2573. PubMed ID: 36881759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense drug discovery and development.
    Yamamoto T; Nakatani M; Narukawa K; Obika S
    Future Med Chem; 2011 Mar; 3(3):339-65. PubMed ID: 21446846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion.
    Shadid M; Badawi M; Abulrob A
    Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1281-1292. PubMed ID: 34643122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
    Guncay A; Yokota T
    Future Med Chem; 2015; 7(13):1631-5. PubMed ID: 26423833
    [No Abstract]   [Full Text] [Related]  

  • 5. Re-Engineering RNA Molecules into Therapeutic Agents.
    Egli M; Manoharan M
    Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.
    Chen S; Le BT; Chakravarthy M; Kosbar TR; Veedu RN
    Sci Rep; 2019 Apr; 9(1):6078. PubMed ID: 30988454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
    Holm A; Hansen SN; Klitgaard H; Kauppinen S
    RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicing.
    Le BT; Paul S; Jastrzebska K; Langer H; Caruthers MH; Veedu RN
    Proc Natl Acad Sci U S A; 2022 Sep; 119(36):e2207956119. PubMed ID: 36037350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets.
    Barresi V; Musmeci C; Rinaldi A; Condorelli DF
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
    Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model.
    Sheng L; Rigo F; Bennett CF; Krainer AR; Hua Y
    Nucleic Acids Res; 2020 Apr; 48(6):2853-2865. PubMed ID: 32103257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of RNA Splicing by Oligonucleotides: Mechanisms of Action and Therapeutic Implications.
    Sergeeva OV; Shcherbinina EY; Shomron N; Zatsepin TS
    Nucleic Acid Ther; 2022 Jun; 32(3):123-138. PubMed ID: 35166605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide.
    Haque US; Yokota T
    Cells; 2023 Oct; 12(19):. PubMed ID: 37830609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short (16-mer) locked nucleic acid splice-switching oligonucleotides restore dystrophin production in Duchenne Muscular Dystrophy myotubes.
    Pires VB; Simões R; Mamchaoui K; Carvalho C; Carmo-Fonseca M
    PLoS One; 2017; 12(7):e0181065. PubMed ID: 28742140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy.
    Aslesh T; Yokota T
    Methods Mol Biol; 2020; 2176():69-85. PubMed ID: 32865783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
    Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy.
    Shabanpoor F; Hammond SM; Abendroth F; Hazell G; Wood MJA; Gait MJ
    Nucleic Acid Ther; 2017 Jun; 27(3):130-143. PubMed ID: 28118087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA-Approved Oligonucleotide Therapies in 2017.
    Stein CA; Castanotto D
    Mol Ther; 2017 May; 25(5):1069-1075. PubMed ID: 28366767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.